<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03770494</url>
  </required_header>
  <id_info>
    <org_study_id>17125</org_study_id>
    <secondary_id>J1F-MC-JZFA</secondary_id>
    <secondary_id>2018-002668-23</secondary_id>
    <nct_id>NCT03770494</nct_id>
  </id_info>
  <brief_title>A Study of LY3405105 in Participants With Advanced Cancer</brief_title>
  <official_title>A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to investigate the safety of LY3405105 in participants with&#xD;
      advanced cancer. The study has two parts phase 1a and phase 1b. Participants will only enroll&#xD;
      in one part.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated for lack of sufficient efficacy.&#xD;
  </why_stopped>
  <start_date type="Actual">January 31, 2019</start_date>
  <completion_date type="Actual">February 4, 2021</completion_date>
  <primary_completion_date type="Actual">February 4, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Baseline through Cycle 1 (28 Day Cycle)</time_frame>
    <description>Number of participants with DLTs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of LY3405105</measure>
    <time_frame>Predose Lead in Day 1 through Predose Cycle 2 Day 1 (28 Day Cycles)</time_frame>
    <description>PK: AUC of LY3405105</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR): Percentage of Participants with a Confirmed Complete Response (CR) or Partial Response (PR)</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated up to 6 Months)</time_frame>
    <description>ORR: Percentage of participants with a Confirmed CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR): Percentage of Participants who Exhibit Stable Disease (SD), Confirmed CR or PR</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated up to 6 Months)</time_frame>
    <description>DCR: Percentage of participants who exhibit SD, Confirmed CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Date of Confirmed CR or PR to Date of Objective Progression or Death Due to Any Cause (Estimated up to 12 Months)</time_frame>
    <description>DOR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Baseline to Date of Confirmed CR or PR (Estimated up to 6 Months)</time_frame>
    <description>TTR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline to Objective Progression or Death Due to Any Cause (Estimated up to 12 Months)</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline to Date of Death from Any Cause (Estimated up to 12 Months)</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>LY3405105</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3405105 administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3405105</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3405105</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Phase 1 a:&#xD;
&#xD;
          -  Have histological or cytological evidence of a diagnosis of a solid tumor cancer that&#xD;
             is advanced and/or metastatic&#xD;
&#xD;
          -  Have available archived tissue for exploratory biomarker analysis&#xD;
&#xD;
          -  Have adequate organ function&#xD;
&#xD;
          -  Have discontinued all previous treatments for cancer and recovered from their side&#xD;
             effects&#xD;
&#xD;
          -  Are able to swallow capsules/tablets&#xD;
&#xD;
        Phase 1 b:&#xD;
&#xD;
          -  Cohort 1: Triple-negative breast cancer (TNBC).&#xD;
&#xD;
          -  Cohort 2: Clear cell ovarian cancer, endometrioid ovarian cancer, or endometrioid&#xD;
             endometrial carcinoma with a LOF mutation in one or more of the following genes:&#xD;
             ARID1A, KMT2C (MLL3), KMT2D (MLL2), or KDM6A (UTX).&#xD;
&#xD;
          -  Cohort 3: Soft tissue sarcoma or sarcomatoid/rhabdoid malignancy with loss of&#xD;
             expression of INI1, BRG1, or BRM by immunohistochemistry or a LOF mutation in one or&#xD;
             more of the following genes: ARID1A, SMARCA2, SMARCA4, or SMARCB1. Participants aged ≥&#xD;
             12 years with a body weight of ≥ 40 kilogram (kg) are acceptable for Cohorts 3.&#xD;
             Participants with synovial sarcoma and a confirmed SS18-SSX gene fusion are also&#xD;
             eligible.&#xD;
&#xD;
          -  Cohort 4: Epithelioid sarcoma with INI1 loss of expression by immunohistochemistry or&#xD;
             SMARCB1 LOF mutation. Participants aged ≥ 12 years with a body weight of ≥ 40 kilogram&#xD;
             (kg) are acceptable for Cohorts 4.&#xD;
&#xD;
          -  Cohort 5: Bladder cancer with a LOF mutation in one or more of the following genes:&#xD;
             ARID1A, KMT2C (MLL3), KMT2D (MLL2), or KDM6A (UTX).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have symptomatic central nervous system (CNS) malignancy or metastasis&#xD;
&#xD;
          -  Have symptomatic human immunodeficiency virus (HIV), Hepatitis A, B, or C&#xD;
&#xD;
          -  Have congestive heart failure&#xD;
&#xD;
          -  Are breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale-New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5TY 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Madrid Norte Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng-Kung Uni. Hosp.</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/ISkx1UpFmMIUiQYaemQSE</url>
    <description>A Study of LY3405105 in Participants With Advanced Cancer</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 7, 2018</study_first_submitted>
  <study_first_submitted_qc>December 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2018</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

